Page 72 - Sohini Das

Power crisis brewing in China likely to hit Indian pharma companies

Delays in consignments, rising prices of key ingredients worry industry

We entered an otherwise hard market with Suburban deal: Dr Lal Pathlabs MD

In a Q&A, Om Manchanda says the firm is now growing organically in the Southern market, but is open to inorganic opportunities there

Covid-19 pandemic: Vaccinating children not a priority for now, say experts

They say mRNA vaccines could offer best protection for vulnerable children

On way to 1 billion doses of Covid-19 vaccines, focus on second jab

Experts say priority should be on second dose to achieve target of vaccinating entire adult population by 2021-end

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Bharat Serums working on polyclonal antibody product for Covid-19 treatment

The company has invested Rs 100 cr in manufacturing capex in the last one year

Single-dose Sputnik Light shows 70% efficacy against Delta variant

RDIF says Sputnik Light can act as a booster shot for even those who have been vaccinated with other vaccines like mRNA candidates

How Gennova is developing India's first indigenous mRNA Covid-19 shot

Where Gennova scores is that it has achieved to crack the stringent sub-zero temperature requirements

Bharat Biotech's Covaxin gets expert panel's nod for children above 2 years

First Covid-19 vaccine in the world for children this young

Vaccines for malaria and dengue may hit Indian market in 2-4 years

There are several candidates in the works - the Serum Institute of India, Bharat Biotech, and Zydus Cadila are working on either developing or manufacturing anti-malarial vaccines

Corporate hospitals expect revenue and margins to surpass pre-Covid times

Non-Covid occupancies, higher average revenue per occupied bed, cost rationalisation driving growth

Expert panel allows adolescent trials of J&J vaccine with riders

SEC asks J&J to monitor adverse events closely for next three months

New-age pharmacy start-ups tap 'kirana' networks, eye US market

New entrants in the largely unorganised Indian pharmaceuticals market are trying out innovative ways to tap a vast market that lies in hinterland

Demerger to give a push to both pharma and financial services: Ajay Piramal

In a Q&A, the Chairman of Piramal Group talks about the prospects of both businesses, the rationale for the demerger and how supply side issues are impacting Indian companies

Piramal Enterprises board approves to demerge and list pharma business

The demerger will give potential investors the option of being associated with the business of their choice

Bharat Biotech submits clinical trial data for paediatric vaccine to DCGI

The vaccine maker added that Covaxin is the first Covid-19 vaccine to be tested in the 2-6-year age group

Covid-19 vaccine needs an injection of pace to keep up with syringe demand

The inoculation programme may suffer from a syringe shortage

WHO technical advisory group to take call on Covaxin EUL next week

Vaccine maker presented data before SAGE working group on Tuesday

Syringe makers expect export of items with low demand in India to continue

Industry estimates India has stockpile to last about a month for Covid-19 vaccination

States not on same page as govt gears up to roll out digital health mission

Tamil Nadu plans parallel programme with unique user IDs